The Venture Codex

Led · Series A · Mar 2026

Founded in 2015, Minnesota Medical Technologies Corporation focuses on continence-care solutions for the millions suffering from fecal incontinence. Its flagship product, StaySure™, is a clinically validated, single-use insert that offers a discreet alternative to adult diapers and invasive surgeries. Developed in collaboration with Mayo Clinic gastroenterologist Dr. Adil Bharucha, the device received FDA clearance in July 2025 after a successful Mayo Clinic clinical trial. The company operates its own medical-device manufacturing facility and is now preparing for full U.S. commercial launch. Proceeds from its recent financing will fund market entry, expand sales and marketing teams, bolster physician and patient education, and strengthen the balance sheet through debt reduction. Management includes veterans from Rochester Medical Corporation, which was sold for $262 million to CR Bard, giving the company seasoned leadership and commercialization experience.

Participated · Series E · Oct 2025

Arthrosi Therapeutics, headquartered in San Diego, is focused on bringing its lead candidate pozdeutinurad (AR882) to market for the treatment of gout and tophaceous gout. Pozdeutinurad is designed as a next-generation, highly potent and selective URAT1 inhibitor that has already demonstrated superior serum urate reduction and complete tophi resolution in Phase 2b studies. The company has fully enrolled two pivotal, 12-month randomized, double-blind, placebo-controlled Phase 3 trials—REDUCE 1 and REDUCE 2—and expects top-line data in Q2 2026. Proceeds from its most recent financing will fund completion of these trials and related development activities. Arthrosi’s strategy is to position pozdeutinurad as a best-in-class therapy addressing the unmet needs of roughly 13 million U.S. gout patients, including about 2 million with tophaceous gout. The company touts a management team with strong execution experience and has attracted a syndicate of life-science investors who see significant commercial potential. While revenue has not yet been generated, the firm’s late-stage clinical progress and sizable Series E raise highlight growing investor confidence in its asset.

Participated · Series A · Aug 2024

Melodi Health raised $10.75M in a Series A financing from HM Venture Partners, Engage Venture Partners, Southeast Minnesota Capital Fund and Three Bridges Private Capital. The company intends to use the funds to further enhance its clinical activities and additional product development activities. Its flagship offering, the Melodi Matrix, is a bioabsorbable mesh that elutes antibiotic agents and is fully absorbed by the body. Melodi announced the launch of the ARIA investigational device exemption (IDE) trial, a multicenter, nationwide, randomized, controlled study evaluating the safety and efficacy of the Melodi Matrix to support an FDA approval for an indication in breast reconstruction. The Melodi Matrix technology was licensed from Medtronic. The company is led by CEO Sarah Worrell and chief medical officer Hunter Moyer, MD, and is based in Minneapolis, MN.